GHRP-2 vs SLU-PP-332
Side-by-side comparison of key properties, dosing, and research.
Growth Hormone Peptides
GHRP-2Recovery & RepairFat Loss & Metabolic
SLU-PP-332- Summary
- GHRP-2 is a potent synthetic hexapeptide that stimulates growth hormone release by activating ghrelin receptors in the pituitary and hypothalamus. It produces one of the strongest GH pulses among GHRPs, though unlike Ipamorelin it does cause modest increases in cortisol and prolactin.
- SLU-PP-332 is a small molecule exercise mimetic that activates estrogen-related receptors ERRalpha and ERRdelta (ERRa/d), transcription factors that drive oxidative metabolism programs. In animal studies it significantly enhanced endurance capacity and metabolic fitness without exercise, mimicking many of the cardiovascular and metabolic adaptations of aerobic training.
- Half-Life
- 15–60 minutes
- Not established in humans; rodent pharmacokinetics suggest hours
- Admin Route
- SubQ, Intranasal
- Oral (research), Subcutaneous (research)
- Research
- —
- —
- Typical Dose
- 100–300 mcg
- Not established for humans; rodent studies used ~100 mg/kg/day
- Frequency
- 2–3 times daily
- Once daily in rodent studies
- Key Benefits
- Strong GH pulse stimulation
- Increased IGF-1 levels
- Enhanced muscle growth and recovery
- Improved fat metabolism
- Better sleep quality
- Increased bone density
- Enhanced appetite (less pronounced than GHRP-6)
- Anti-aging effects via GH axis optimization
- Significant enhancement of aerobic endurance capacity
- Increases mitochondrial density and oxidative metabolism in muscle
- Promotes beneficial shift toward oxidative muscle fiber phenotype
- Improves cardiac efficiency and cardiovascular fitness markers
- Potential for obesity, metabolic syndrome, and heart failure treatment
- Exercise mimetic for populations unable to exercise (disability, frailty, disease)
- Side Effects
- Increased appetite
- Water retention
- Elevated cortisol (modest)
- Elevated prolactin (modest)
- +2 more
- Limited human data; all studies are preclinical (rodent)
- Unknown cardiovascular effects with long-term or high-dose use in humans
- Potential hormonal interactions via ERR pathway (ERRs modulate estrogen-related signaling)
- Off-target effects not fully characterized
- Stacks With
- —
- —